1. Home
  2. MGRX vs IMNN Comparison

MGRX vs IMNN Comparison

Compare MGRX & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mangoceuticals Inc.

MGRX

Mangoceuticals Inc.

BUY

Current Price

$0.26

Market Cap

7.1M

Sector

Technology

ML Signal

BUY

Logo Imunon Inc.

IMNN

Imunon Inc.

HOLD

Current Price

$1.25

Market Cap

7.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGRX
IMNN
Founded
2021
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1M
7.9M
IPO Year
2023
2000

Fundamental Metrics

Financial Performance
Metric
MGRX
IMNN
Price
$0.26
$1.25
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $17.00
AVG Volume (30 Days)
★ 522.9K
98.7K
Earning Date
11-13-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 55.17
N/A
EPS
★ N/A
N/A
Revenue
★ $456,021.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.26
$0.96
52 Week High
$2.50
$4.93

Technical Indicators

Market Signals
Indicator
MGRX
IMNN
Relative Strength Index (RSI) 30.21 50.77
Support Level N/A $0.96
Resistance Level $0.49 $1.59
Average True Range (ATR) 0.04 0.09
MACD -0.02 0.02
Stochastic Oscillator 2.60 73.61

Price Performance

Historical Comparison
MGRX
IMNN

About MGRX Mangoceuticals Inc.

Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.

Share on Social Networks: